KTTA Fundamental Analysis - PASITHEA THERAPEUTICS CORP

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to KTTA. KTTA was compared to 559 industry peers in the Biotechnology industry. KTTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KTTA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

KTTA had negative earnings in the past year.

KTTA had a negative operating cash flow in the past year.

KTTA had negative earnings in each of the past 5 years.

In the past 5 years KTTA always reported negative operating cash flow.

1.2 Ratios

KTTA has a Return On Assets of -92.82%. This is in the lower half of the industry: KTTA underperforms 74.06% of its industry peers.

With a Return On Equity value of -104.84%, KTTA perfoms like the industry average, outperforming 44.01% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-92.82%
ROE	-104.84%
ROIC	N/A

ROA(3y)-32.01%

ROA(5y)N/A

ROE(3y)-35.08%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

KTTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KTTA has more shares outstanding than it did 1 year ago.

KTTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

KTTA has an Altman-Z score of -5.44. This is a bad value and indicates that KTTA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.44, KTTA is doing worse than 61.36% of the companies in the same industry.

There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.44

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

KTTA has a Current Ratio of 3.84. This indicates that KTTA is financially healthy and has no problem in meeting its short term obligations.

KTTA has a Current ratio of 3.84. This is comparable to the rest of the industry: KTTA outperforms 43.65% of its industry peers.

KTTA has a Quick Ratio of 3.84. This indicates that KTTA is financially healthy and has no problem in meeting its short term obligations.

KTTA's Quick ratio of 3.84 is in line compared to the rest of the industry. KTTA outperforms 45.98% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.84
Quick Ratio	3.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.22% over the past year.

EPS 1Y (TTM)24.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56.45%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KTTA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KTTA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PASITHEA THERAPEUTICS CORP

NASDAQ:KTTA (6/10/2025, 8:00:02 PM)

After market: 0.8993 +0.02 (+2.05%)

0.8812

-0.02 (-2.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-15 2025-05-15

Earnings (Next)08-11 2025-08-11

Inst Owners6.4%

Inst Owner Change2.32%

Ins Owners8.78%

Ins Owner Change-0.02%

Market Cap6.56M

Analysts82.86

Price TargetN/A

Short Float %7.5%

Short Ratio0.07

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.51
P/tB	1.44
EV/EBITDA	N/A

EPS(TTM)-10.72

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.7

FCFYN/A

OCF(TTM)-1.7

OCFYN/A

SpS0

BVpS1.74

TBVpS0.61

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-92.82%
ROE	-104.84%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-32.01%

ROA(5y)N/A

ROE(3y)-35.08%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.84
Quick Ratio	3.84
Altman-Z	-5.44

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)1213.67%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)24.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%56.45%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y17.36%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-132.04%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-137.95%

OCF growth 3YN/A

OCF growth 5YN/A

PASITHEA THERAPEUTICS CORP (KTTA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens